0001209191-21-045554.txt : 20210706
0001209191-21-045554.hdr.sgml : 20210706
20210706170128
ACCESSION NUMBER: 0001209191-21-045554
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210701
FILED AS OF DATE: 20210706
DATE AS OF CHANGE: 20210706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MORE ROBERT J
CENTRAL INDEX KEY: 0001207792
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 211074933
MAIL ADDRESS:
STREET 1: 680 S CACHE STREET, SUITE 100
STREET 2: BOX 10820
CITY: JACKSON
STATE: WY
ZIP: 83001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 499 ILLINOIS STREET
STREET 2: SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-01
0
0001706431
Vir Biotechnology, Inc.
VIR
0001207792
MORE ROBERT J
C/O VIR BIOTECHNOLOGY, INC.
499 ILLINOIS STREET, SUITE 500
SAN FRANCISCO
CA
94158
1
0
0
0
Common Stock
2021-07-01
4
S
0
4794
44.3065
D
64575
D
Common Stock
2021-07-01
4
S
0
5986
45.2275
D
58589
D
Common Stock
2021-07-01
4
S
0
890
46.2169
D
57699
D
Common Stock
486111
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.81 to $44.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.91 to $46.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The shares are held by APNG 1. The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. However, the reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
/s/ Howard Horn, Attorney-in-Fact
2021-07-06